Asthma is a co-morbid condition associated with increased rates of pain, acute chest syndrome and premature death in human sickle cell disease (SCD). We developed an experimental asthma model in SCD and control mice expressing either normal human or murine hemoglobin to determine its effect on mortality and lung pathology. To induce lung inflammation, experimental mice were sensitized to ovalbumin (OVA) by subcutaneous OVA implantation (Sen), allowed 2 wks to recover and then divided into 2 groups, each receiving over a subsequent 10 day period, the same dosage of aerosolized OVA but 2 different levels of exposure; 15 min (LoSen) and 30 min (HiSen). During recovery, 10% of SCD mice died compared to no deaths in control mice. An additional 30% of HiSen SCD mice died during aerosolization compared to 10% in LoSen SCD. Histological indices of lung inflammation (e.g., eosinophil recruitment, airway and vessel wall thickening, immunoreactive TGFβ and fsp-1) and bronchial alveolar lavage fluid eosinophil peroxidase activity differentially increased in sensitized mice compared to unsensitized mice. Our findings indicate SCD mice with experimentally-induced asthma are more susceptible to death and pulmonary inflammation compared to control mice suggesting that asthma contributes significantly to morbidity and mortality in SCD.
Introduction
The major causes of morbidity and mortality in sickle cell disease (SCD) are initiated by tissue ischemia and infarction due to vascular occlusion that results in progressive organ damage.
The etiology of vaso-occlusion is unclear and likely reflects the complex interplay between the sickle red blood cell, the injured vessel wall and increased inflammation. In support of this notion, there is considerable evidence for increased inflammation in both human and murine SCD. The leukocyte count is elevated in SCD and correlates with a more severe clinical course, including increased risk of stroke and early death. [1] [2] [3] [4] Additionally, patients with SCD have chronically elevated acute phase proteins, which often increase further during crisis. 5 The fact that patients with SCD have increased numbers of circulating endothelial cells that increase to even higher levels during times of vaso-occlusive crises, provide strong evidence that endothelial inflammation and injury play important roles in the mechanisms impairing vascular function in SCD. 6 These circulating endothelial cells express an activated phenotype, including increased expression of the adhesive molecules VCAM-1, E-selectin and ICAM-1. 6 In parallel with these human studies, additional experiments showed that sickle cell disease mice also have increased circulating endothelial cells that express higher levels of E-selectin, VCAM and ICAM-1. 7 Other studies have shown that sickle cell disease increases the expression of tissue factor in the veins of the lungs in response to ischemia/reperfusion by a mechanism that can be inhibited by lovastatin. 8 Moreover, plasma levels of the proinflammatory cytokines IL-1β, IL-6, IFN-γ, and TNF-α are sometimes elevated in human SCD at steady state, with further increases during acute vaso-occlusive events. 9 Again, with respect to developing relevant murine models of human disease, levels of IL-6 are elevated in SCD mice. 10 For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From
To further support the claim that SCD is a "proinflammatory state," Holtzclaw et al. found that transgenic SCD mice have increased mortality and exaggerated inflammatory responses to low dose LPS challenge compared to control mice. 11 This included elevated levels of TNF-α, IL-1β and soluble VCAM-1 in the serum and bronchoalveolar lavage fluid of SCD mice. Taken together, these studies in individuals with SCD and experimental murine models of SCD suggest that sickle cell anemia increases inflammation.
Asthma is common among African Americans, the population in the United States that is predominantly affected with SCD, with a prevalence in non-Hispanic African-American individuals of at least 9%. 12 As an inflammatory, co-morbid condition, asthma likely contributes to sickle hemoglobin-induced vascular and organ pathologies. 12 To support the global hypothesis that inflammation may increase SCD morbidity and mortality, we recently demonstrated that a diagnosis of asthma among children with SCD significantly increases the incidence of pain and acute chest syndrome when compared to children without asthma.
13,14
Furthermore, we have shown that, among individuals with SCD, asthma is an independent risk factor for death. 15 On the basis of these reports it seems logical to view asthma as a co-morbid condition in SCD that has significant adverse effects on the health of SCD individuals, including increasing the risk of death.
To evaluate the contribution of chronic airway inflammation to SCD pathologies, we examined the effects of experimentally-induced asthma on mortality and lung pathology in a murine model of severe SCD. Asthma-like pathological changes were induced in mice using a modified ovalbumin (OVA) sensitization protocol previously established in C57BL/6 mice. 16, 17 We found that SCD mice have exaggerated inflammatory responses to OVA sensitization compared to control mice. OVA Sensitization: SCD, HbA and WT mice were either placed into a control un-sensitized (UnSen) group or an ovalbumin (OVA) sensitized (Sen) group. OVA sensitization was achieved using a modification of a protocol previously described by de Siqueira et al. 16 ( Figure 1 Mice that died and were included in the mortality statistics (Figure 2 ), died approximately 3-4 days after surgical implantation of the OVA fragment, indicating that death was unlikely related to complications of anesthesia.
Histopathology: The standard protocol for fixing the lungs was to inflate the lung with 0.5 mL of PBS-Zn-formalin prior to removal. The tissues were embedded in paraffin, sections cut Nuclei were counterstained for 3 min at room temperature with TO-PRO®-3 iodide (642nm/661nm) (Invitrogen-Molecular Probes, Inc., OR Cat. # T3605). The slides were washed,
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From mounted and images captured on a krypton argon laser Nikon Eclipse TE2000U confocal microscope using 10X objective/0.17 aperture with the total magnification of 100 (Ex/Em at 488nm/580nm for FITC and 633nm/661nm for To-Pro3) and IBM EXC1 software. Staining controls were slides incubated in the absence of the primary antibodies.
Total IgE Assay: Total IgE was determined as previously described. 17 Blood was collected directly from the heart into heparin and plasma separated from red cells, aliquotted and stored at -80ºC until analysis. Total IgE was measured by enzyme-linked immunosorbent assay (ELISA).
Briefly, 96 well flat-bottom polystyrene microplates (Fisher Scientific) were coated with antimouse IgE (2 μg/mL, 100 μL/well, 4h at room temp, then 12 h at 4ºC)(PharMingen, San Diego, CA). After washing with PBS-Tween, the plates were blocked with 1% bovine serum albumin (BSA, Sigma) for 1 h and the wells washed again. Serially diluted standards and test samples were then added to the plate and incubated for 12 h at 4ºC. Following another set of washes, biotinylated anti-mouse IgE was added to the well (PharMingen, room temperature, 1h). Excess 
Bronchoalveolar lavage fluid (BALF) eosinophil peroxidase (EPO) Activity:
After collecting the blood, the trachea of the mouse was cannulated and the lungs washed with PBS (0.8 mL, 5x, 25ºC). BALF was collected and centrifuged to isolate suspended cells. The pelleted cells and the cell free supernatant were separated and stored at -80ºC until analysis. EPO activity was determined on the isolated cells by using a modified method of Schneider et al. 22 Briefly, the BALF cell pellet was re-suspended in 0.5 mL of PBS, sonicated for 1 min and then centrifugated Statistical analysis: For the analysis of survival, a Kaplan-Meier Analysis was performed with statistical significance determined by a log rank (Mantel-Cox) test. For the parameters of histological and morphometric data, a two-way ANOVA was performed (mouse group by level of sensitization) to determine the statistical differences between groups and their response to 2 levels of OVA sensitization. When a significant difference was found, the Tukey's test was performed in the post hoc analysis to determine significant differences between experimental conditions. Analysis was performed with the SigmaStat (SysStat Inc.) or Prism Graph Pad (v4.0). Values are expressed as means ± SEM unless otherwise specified.
Results

Mortality:
The rate of death was higher in SCD mice compared to WT or HbA mice. Ten percent of SCD mice died after Day 5 following OVA implantation (P < 0.01, Figure 2A Figure 2B ).
Blood Markers of Sensitization -Total IgE:
Marked increases in total IgE levels are often indicative of active asthma. 23 OVA sensitization significantly increased IgE concentrations in WT-Lo or WT-Hi mice compared with WT-Un mice ( Figure 3A) . Although sensitization increased IgE in HbA mice, significance was not achieved. In contrast, sensitization of SCD mice markedly increased IgE. Moreover, IgE levels in SCD-Hi mice were increased more than in the WT-Hi or HbA-Hi mice ( Figure 3A ).
Blood Markers of Sensitization -Peripheral Blood Eosinophils:
Increased peripheral blood eosinophil counts directly correlate with severity of asthma in humans 24 and mice. 25 OVA sensitization markedly increased eosinophils in both WT-Lo and WT-Hi mice compared with WT-Un mice ( Figure 3B ). Similarly, OVA-sensitization significantly increased eosinophil counts in both SCD-Lo and SCD-Hi mice compared with SCD-Un mice. In contrast, eosinophil counts in HbA-Lo mice were more modest and not significantly different from HbA-Un mice, thickening in all three groups compared to UnSen groups (P < 0.05). In contrast, peribronchial and perivascular thickening in SCD-Lo mice were already increased to the same level as SCD-Hi mice, presumably a maximal inflammatory response ( Figures 6B and 6C ). These data demonstrate that the inflammatory response of collagen deposition in SCD mice is accentuated compared to other sensitized groups.
Lung Markers of Inflammation -BALF EPO
Immunofluorescence of TGFβ and fsp-1:
TGFβ expression is commonly increased in asthma. 26 Figure 7A) . Interestingly, TGFβ expression in untreated animals was increased in SCD compared to UnSen WT and HbA mice. With the exception of the higher baseline levels of expression in UnSen SCD mice, these data are consistent with the increase in collagen deposition ( Figure 6 ).
OVA-sensitization markedly increased TGFβ expression in the lungs of WT, HbA and SCD
Fibroblast specific protein-1 (fsp-1) is expressed on fibroblasts and on cells transitioning into fibroblasts. 27 The overall pattern of fsp-1 expression in all groups of mice appears similar to the pattern of TGFβ expression (Figure 7 ). At baseline, SCD-Un mice express higher levels of fsp-1 than HbA-Un and WT-Un mice. OVA-sensitization increased fsp-1 expression in all groups with a slight greater level of expression in HbA mice and an exaggerated level of expression in SCD mice. These data suggest that fsp-1 expression in OVA-sensitized mice is increased in SCD mice to a greater extent than in controls.
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Discussion
We developed a novel model of experimentally-induced asthma in Berkeley SCD mice. 18 Our findings show that experimentally-induced asthma increases mortality of SCD mice and that SCD mice exhibit exaggerated responses to allergen-induced lung inflammation. This conclusion is based on our observations that, in general, OVA-sensitization increases recruitment of eosinophils, thickening of airways and vessels and collagen deposition to high levels in SCD mice after either LoSen or HiSen OVA sensitization, while controls generally exhibited moderate inflammation when exposed to the LoSen protocol, but could reach maximal levels of inflammation when exposed to the HiSen protocol. Consistent with these findings, TGFβ and fsp-1 expression in SCD mice were also increased to higher levels in SCD mice at both baseline and after exposure to LoSen protocol compared with controls. Maximal inflammatory responses in WT and HbA mice were achieved only when these controls were exposed to the HiSen protocol.
Several models of experimentally-induced asthma have been developed to study mechanisms of pulmonary inflammation and fibrosis. Agents used for sensitization range from allergens, fungi, nematodes to viruses. One of the most common methods for increasing bronchopulmonary inflammation is sensitizing with a specific antigen and a Th-2 skewing adjuvant, such as aluminium hydroxide (alum). Typically OVA is adsorbed onto alum and then injected either subcutaneously or intraperitoneally, followed by OVA intranasally or via aerosolization. To induce experimental asthma in SCD mice we modified an OVA model that was previously optimized for C57BL/6 mice. 17 Our model is similar to others, in that, it develops asthma-like histopathology and inflammation with eosinophil infiltration that is similar to that which develops in humans. For example, peripheral blood eosinophil counts (as percent of total WBCs) in the OVA-sensitized mice increased in direct relation to quantitative measures of histopathologic eosinophil infiltration within the lungs (r=0.9229, see on-line Supplemental Data). However, our model differs from others, in that, pulmonary inflammation develops early, typically within less than one month, even without multiple IP or subcutaneous antigen injections. Another way this model differs from others is that systemic sensitization was induced by subcutaneous implantation of denatured OVA.
Based on observations in humans, 13, 14 we hypothesized that asthma would be a co-morbid condition that would increase susceptibility to death in an established murine model of SCD.
Our survival data are consistent with this hypothesis. For example, ~40% of SCD-Hi mice died (~10% after OVA implantation, ~30% after OVA aerosolization) whereas the HiSen protocol had little to no effect on survivability of HbA or WT mice. Indeed, one of our concerns in establishing this model in SCD mice was increased mortality, potentially limiting end point data.
Fortunately, lowering OVA exposure from 30 to 15 min reduced mortality rates to levels that were statistically indistinguishable from controls, yet provides sufficient numbers with which to assess changes in pulmonary inflammation. While we do not have definitive data on the cause of death in SCD mice, we speculate that the marked increase in airway inflammation induced by the HiSen protocol combined with an existing increased baseline in systemic chronic inflammation that is typically observed in human and murine SCD, likely contributed to the higher mortality rates in the SCD mice.
Similarly, our hypothesis that SCD mice would have greater inflammatory responses to OVA sensitization than healthy controls is clearly supported by our findings. Our data suggest that the LoSen protocol induces maximal inflammatory responses in SCD mice because further increases in histopathological indices were not achieved in SCD mice exposed to the HiSen protocol. In agreement, the HiSen protocol induced "maximal" increases in eosinophil recruitment, thickening of airways and vessels or collagen deposition that were similar in all 3 groups. However, the increased death rate observed in HiSen versus LoSen SCD mice (30% vs.
10% deaths, respectively) suggests that prolonged OVA exposure induces additional detrimental physiologic changes that go beyond our current histologic measures of lung inflammation.
Pulmonary function testing and measures of oxygen delivery to tissues in vivo would help to further clarify the physiologic impact of OVA-induced sensitization in this murine model of SCD.
It is interesting that the perialveolar and perivascular eosinophil scores for HbA-Hi and SCD-Hi mice were similar, but the mortality rates were different (although the total IgE was higher in SCD-Hi mice compared to the other groups). We theorize that this result occurred because maximal levels of sensitization were achieved when mice were exposed to the HiSen protocol. SCD mice however, have additional complications resulting from chronic organ damage and ongoing sickling of red cells that are evident at baseline. Such complications may have contributed to higher mortality rates for SCD mice in the same way as is observed for humans with SCD. 15 As the cause of death in our mice was not determined, it is difficult to say why SCD-Hi mice died more frequently. However, because most of the mice that died were SCD mice, it seems logical to conclude that sickle hemoglobin-induced RBC and vascular pathologies contributed significantly to the cause of death. Furthermore, these data are similar to Holtclaw et al., where sublethal LPS caused death in 60% of SCD mice compared to <5% in control mice. 11 Thus, SCD mice may be predisposed to exaggerated inflammatory responses regardless of the source, including pulmonary allergens. This conclusion is based in part on observations that the LoSen protocol induced inflammatory responses in SCD mice that were essentially equivalent to the maximal responses induced in SCD mice exposed to the HiSen protocol. In contrast, the LoSen protocol induced inflammatory responses in the WT and HbA mice that were approximately half of that induced by the HiSen protocol. Thus, our findings demonstrate that SCD mice are "primed" for exaggerated inflammatory responses.
In many respects, findings here parallel those in humans with SCD. First, the Berkeley SCD mice are fragile animals that are susceptible to red cell congestion, exaggerated oxidative lung injury 28 and increased chronic inflammation 10 just as individuals with SCD. [29] [30] [31] [32] [33] [34] [35] Secondly, SCD mice with co-morbid experimentally-induced "asthma" have increased rates of mortality when compared to SCD mice without asthma. These results are similar to the increased death rates among individuals with SCD and asthma when compared to SCD individuals without asthma. 15 Exactly what makes humans with SCD and asthma-like symptoms more susceptible to death, painful vaso-occlusive events and acute chest syndrome is unknown. However, it is well recognized that SCD increases vascular inflammation and injury. [30] [31] [32] [33] [34] [35] Accordingly, pulmonary vascular beds in humans with SCD may also be predisposed to an exaggerated inflammatory response in the clinical setting of co-morbid asthma. Such changes begin to explain the increased incidence of acute chest syndrome, acute painful vaso-occlusive events and premature death observed in individuals with both SCD and asthma. Regardless how this proinflammatory state begins and evolves, our findings demonstrate that SCD mice are "primed" for exaggerated responses to OVA sensitization.
The role of eosinophils in asthma is controversial, in that, they have the ability to both repair and injure pulmonary tissue. 26 Eosinophils express TGFβ in the latent state that can be activated by α v β 6 integrin on epithelial cells 36 as well as by mast cell tryptase. 37 Interestingly, genetic deletion of catalase increases oxidative stress, TGFβ and fsp-1 expression and fibrosis. 38 TGFβ, after activation, is well recognized for increasing fsp-1 expression, accelerating the transition of epithelial cells into mesenchymal cells and increasing fibrosis. 39 It should be noted that extracellular oxidant stress also activates TGFβ which, in turn, increases pulmonary fibrosis. 40 On the basis of these reports, chronic states of oxidative stress and inflammation in SCD mice may play an important role in increasing TGFβ expression and activation in SCD-Un mice. Our data suggests that OVA sensitization exaggerates inflammatory and fibrotic responses in SCD mice compared to WT and HbA mice. As increased pulmonary fibrosis and inflammation correlate with impaired lung function, such differences may explain why sickle cell predisposes SCD mice to increased morbidity and mortality.
To our knowledge this is the first model of experimentally-induced asthma in a murine model of severe SCD. As such, these mice provide unique opportunities to study the mechanism driving airway disease in SCD as well as to dissect the role of inflammation in sickle hemoglobin-induced pulmonary and systemic organ pathologies. With this murine model of experimental asthma and SCD, we can begin to explore new mechanisms by which different inflammatory cells and pathways participate in the asthmatic inflammatory process. For example, blood from these mice could be analyzed to determine if and the extent to which eosinophils, neutrophils and/or monocytes/macrophages are activated. A full complement of cytokines could be quantified to follow the time course of the inflammatory response to OVA sensitization. The experimentally-induced asthma SCD mouse could also be used to test clinically relevant therapies, such as supplemental oxygen, bronchodilators, specific antiinflammatory therapies to identify the most effective means of attenuating inflammation in the SCD lung. Finally, the OVA-sensitized SCD mice could be helpful in delineating fundamental mechanisms to explain why children with SCD and asthma are more susceptible to systemic and pulmonary vaso-occlusive events and are at increased risk for premature death.
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